Country: United Kingdom
Language: English
Source: MHRA (Medicines & Healthcare Products Regulatory Agency)
Losartan potassium
DE Pharmaceuticals
C09CA01
Losartan potassium
50mg
Oral tablet
Oral
No Controlled Drug Status
Valid as a prescribable product
BNF: 02050502
PACKAGE LEAFLET: INFORMATION FOR THE USER COZAAR ® 50MG TABLETS (losartan potassium) READ ALL OF THIS LEAFLET CAREFULLY BEFORE YOU START TAKING THIS MEDICINE BECAUSE IT CONTAINS IMPORTANT INFORMATION FOR YOU. Keep this leaflet. You may need to read it again. If you have any further questions, ask your doctor, pharmacist or nurse. This medicine has been prescribed for you only. Do not pass it on to others. It may harm them, even if their signs of illness are the same as yours. If you get any side effects, talk to your doctor, pharmacist, or nurse. This includes any possible side effects not listed in this leaflet. See section 4. The name of your medicine is Cozaar 50mg tablets but will be referred to as Cozaar throughout this leaflet. Please note that this leaflet also contains information about other strengths Cozaar 12.5mg, 25mg and 100mg tablets. WHAT IS IN THIS LEAFLET 1. What Cozaar is and what it is used for 2. What you need to know before you take Cozaar 3. How to take Cozaar 4. Possible side effects 5. How to store Cozaar 6. Contents of the pack and other information Losartan (Cozaar) belongs to a group of medicines known as angiotensin-II receptor antagonists. Angiotensin-II is a substance produced in the body which binds to receptors in blood vessels, causing them to tighten. This results in an increase in blood pressure. Losartan prevents the binding of angiotensin-II to these receptors, causing the blood vessels to relax which in turn lowers the blood pressure. Losartan slows the decrease of kidney function in patients with high blood pressure and type 2 diabetes. Cozaar is used to treat patients with high blood pressure (hypertension) in adults and in children and adolescents 6 - 18 years of age. to protect the kidney in hypertensive type 2 diabetic patients with laboratory evidence of impaired renal function and proteinuria ≥ 0.5 g per day (a condition in which urine contains an abnormal amount of protein). to treat patients with chronic heart failure when therapy with Read the complete document